Terms: = Ovarian cancer AND ER, estrogen receptor AND Diagnosis
271 results:
1. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or ovarian cancer.
Torres-Esquius S; Llop-Guevara A; Gutiérrez-Enríquez S; Romey M; Teulé À; Llort G; Herrero A; Sánchez-Henarejos P; Vallmajó A; González-Santiago S; Chirivella I; Cano JM; Graña B; Simonetti S; Díaz de Corcuera I; Ramon Y Cajal T; Sanz J; Serrano S; Otero A; Churruca C; Sánchez-Heras AB; Servitja S; Guillén-Ponce C; Brunet J; Denkert C; Serra V; Balmaña J
JAMA Netw Open; 2024 Apr; 7(4):e247811. PubMed ID: 38648056
[TBL] [Abstract] [Full Text] [Related]
2. [Non-primary solid malignancies of breast in needle core biopsy: a clinicopathological analysis of 23 cases].
Gu WQ; Wang L; Xu JC; Ping GQ; Han X; Wang C
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):331-336. PubMed ID: 38556815
[No Abstract] [Full Text] [Related]
3. Mesonephric-like adenocarcinoma of the ovary.
Yang Y; Zhao M; Jia Q; Tang H; Xing T; Li Y; Tang B; Xu L; Wei W; Zheng H; Shi R; Xia B; Chen J
J Ovarian Res; 2024 Mar; 17(1):57. PubMed ID: 38444000
[TBL] [Abstract] [Full Text] [Related]
4. To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma.
Yadav A; Sistla A; Swain M; Gowrishankar S; Padua M; Modi T; Himabindu R; Agarwal N; Kulkarni A; Bhandari T; Vudayaraju H; Chinnababu ; Reddy VA
Indian J Pathol Microbiol; 2024; 67(1):62-67. PubMed ID: 38358190
[TBL] [Abstract] [Full Text] [Related]
5. Trichorhinophalangeal Syndrome Type 1 Immunohistochemical Expression in Carcinomas of Gynecologic Origin.
Ruiz F; Tjendra Y; Millan N; Gomez-Fernandez C; Pinto A
Am J Surg Pathol; 2024 May; 48(5):546-550. PubMed ID: 38357982
[TBL] [Abstract] [Full Text] [Related]
6. The management of uterine tumor resembling an ovarian sex cord tumor (UTROSCT): case series and literature review.
Lin J; Liu L; Wang L; Ma N; Zhang K; Xie N; Yu H; Deng S; Sun Y
World J Surg Oncol; 2024 Feb; 22(1):42. PubMed ID: 38310233
[TBL] [Abstract] [Full Text] [Related]
7. PAX2 is regulated by estrogen/progesterone through promoter methylation in endometrioid adenocarcinoma and has an important role in carcinogenesis via the AKT/mTOR signaling pathway.
Chen H; Li L; Liu H; Qin P; Chen R; Liu S; Xiong H; Li Y; Yang Z; Xie M; Yang H; Jiang Q
J Pathol; 2024 Apr; 262(4):467-479. PubMed ID: 38185904
[TBL] [Abstract] [Full Text] [Related]
8. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Wang Y; Broeks A; Giardiello D; Hauptmann M; Jóźwiak K; Koop EA; Opdam M; Siesling S; Sonke GS; Stathonikos N; Ter Hoeve ND; van der Wall E; van Deurzen CHM; van Diest PJ; Voogd AC; Vreuls W; Linn SC; Dackus GMHE; Schmidt MK
Eur J Cancer; 2023 Dec; 195():113401. PubMed ID: 37925965
[TBL] [Abstract] [Full Text] [Related]
9. Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan.
Muhammad N; Azeem A; Bakar MA; Prajzendanc K; Loya A; Jakubowska A; Hamann U; Rashid MU
Breast Cancer Res Treat; 2023 Nov; 202(2):377-387. PubMed ID: 37528266
[TBL] [Abstract] [Full Text] [Related]
10. High-grade Serous Carcinoma can Show Squamoid Morphology Mimicking True Squamous Differentiation.
Tomonobe H; Ohishi Y; Hachisuga K; Yahata H; Kato K; Oda Y
Am J Surg Pathol; 2023 Sep; 47(9):967-976. PubMed ID: 37382102
[TBL] [Abstract] [Full Text] [Related]
11. Controlled ovarian hyperstimulation in breast cancer patients: Does oestrogen receptor status make a difference?
Sii S; Polyakov A; Rozen G; Agresta F; Stern K
Aust N Z J Obstet Gynaecol; 2023 Dec; 63(6):774-779. PubMed ID: 37317583
[TBL] [Abstract] [Full Text] [Related]
12. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast cancer.
Bukamal Z; AlRayes A
Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
[TBL] [Abstract] [Full Text] [Related]
13. [A Case of De Novo Stage Ⅳ Breast cancer with Umbilical Metastasis and Peritoneal Dissemination].
Mitsuyoshi A; Yanagawa T; Kikumori K; Hori A; Oshima K; Shinke G; Katsuyama S; Ikeshima R; Hiraki M; Ohmura Y; Sugimura K; Masuzawa T; Hata T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2023 Mar; 50(3):366-368. PubMed ID: 36927911
[TBL] [Abstract] [Full Text] [Related]
14. Immunohistochemical markers of prognosis in adult granulosa cell tumors of the ovary - a review.
Jung D; Almstedt K; Battista MJ; Seeger A; Jäkel J; Brenner W; Hasenburg A
J Ovarian Res; 2023 Mar; 16(1):50. PubMed ID: 36869369
[TBL] [Abstract] [Full Text] [Related]
15. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.
Němejcová K; Šafanda A; Bártů MK; Michálková R; Drozenová J; Fabian P; Hausnerová J; Laco J; Matěj R; Méhes G; Škapa P; Stružinská I; Dundr P
Diagn Pathol; 2023 Feb; 18(1):32. PubMed ID: 36855066
[TBL] [Abstract] [Full Text] [Related]
16. The impact of coding germline variants on contralateral breast cancer risk and survival.
Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; ; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; ; Jakubowska A; Jung AY; Keeman R; Kristensen VN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mavroudis D; Milne RL; Mulligan AM; Newman WG; Park-Simon TW; Peterlongo P; Pharoah PDP; Rhenius V; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Spurdle AB; Tomlinson I; Truong T; van Veen EM; Vreeswijk MPG; Wang Q; Wendt C; Yang XR; Nevanlinna H; Devilee P; Easton DF; Schmidt MK
Am J Hum Genet; 2023 Mar; 110(3):475-486. PubMed ID: 36827971
[TBL] [Abstract] [Full Text] [Related]
17. A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer.
Mo J; Ruan S; Yang B; Jin Y; Liu K; Luo X; Jiang H
J Zhejiang Univ Sci B; 2023 Jan; 24(1):64-77. PubMed ID: 36632751
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathologic Review of Metastatic Breast cancer to the Gynecologic Tract.
Braun A; Reddy S; Cheng L; Gattuso P; Yan L
Int J Gynecol Pathol; 2023 Jul; 42(4):414-420. PubMed ID: 36563298
[TBL] [Abstract] [Full Text] [Related]
19. ovarian removal and subsequent breast cancer prognosis: a nationwide cohort study.
Gottschau M; Kjær SK; Viuff JH; Jensen A; Munk C; Settnes A; Mellemkjær L
Breast Cancer Res Treat; 2023 Feb; 197(3):583-591. PubMed ID: 36482232
[TBL] [Abstract] [Full Text] [Related]
20. Clinicopathologic Features and the Loss of ARID1A Expression in ovarian Seromucinous Borderline Tumors and Seromucinous Carcinomas.
Ok Atılgan A; Özen Ö; Haberal Reyhan AN; Ayhan A
Int J Surg Pathol; 2023 Jun; 31(4):398-408. PubMed ID: 36452965
[TBL] [Abstract] [Full Text] [Related]
[Next]
